# Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

> **NCT07103447** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shuangyue Liu** · enrollment: 54 (estimated)

## Conditions studied

- Breast Cancer - Female

## Interventions

- **DRUG:** AK112, Carboplatin, Paxlitaxel

## Key facts

- **NCT ID:** NCT07103447
- **Lead sponsor:** Shuangyue Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07103447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07103447, "Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07103447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*